Most popular wellness peptides are still not legal to compound
As of October 27, 2026, no peptide from the 2026 debate has been added to the FDA's 503A bulks list. An interim access policy that could change that is under White House review.
This tracker shows the current FDA status of the peptides people search for most. We update it whenever the FDA, its advisory committee, or the White House budget office acts.
How to read the table
FDA-approved means the FDA has reviewed clinical trial data and approved a specific product for a specific use. It's the highest bar.
Can pharmacies compound it? is a separate question. A compounding pharmacy can only make a custom version of a drug from an ingredient that meets federal rules, such as being on the FDA's 503A bulks list. For most wellness peptides, the answer today is no. Our explainer on Category 1 vs. Category 2 covers how that system works.
Under review means something is actively moving: an advisory committee vote, a scheduled meeting, or a pending policy. It does not mean a peptide is legal to compound yet.
What changed most recently
On October 14, 2026, the FDA sent an "Interim Access Policy for Compounding Using Certain Peptides" to the White House Office of Management and Budget for review. Its text hasn't been published. News reports say it could let pharmacies temporarily compound some peptides, possibly including BPC-157, while the FDA finishes its formal rulemaking. Until the policy is released and takes effect, nothing in the table changes.
| Peptide | Status | FDA-approved? | Can pharmacies compound it? | Where it stands | Next milestone |
|---|---|---|---|---|---|
| BPC-157 | Under review | No | No | Taken off the Category 2 safety list in April 2026. An FDA advisory panel recommended it 8–6 on July 23, 2026; FDA staff had opposed. No proposed rule yet. | Interim access policy under White House review since Oct 14, 2026 |
| TB-500 | Under review | No | No | Same path as BPC-157: off Category 2 in April 2026, recommended 8–6 by the advisory panel on July 23, 2026, against FDA staff advice. | Interim access policy; FDA proposed rule |
| KPV | Under review | No | No | Recommended 8–6 by the advisory panel on July 23, 2026. FDA staff opposed. | Interim access policy; FDA proposed rule |
| MOTS-c | Under review | No | No | Recommended 7–5 (two abstentions) by the advisory panel on July 23, 2026. FDA staff opposed. | Interim access policy; FDA proposed rule |
| Semax | Under review | No | No | Recommended by the advisory panel on July 24, 2026. FDA staff opposed. | FDA proposed rule |
| Epitalon | Under review | No | No | Recommended by the advisory panel on July 24, 2026. FDA staff opposed. | FDA proposed rule |
| Emideltide (DSIP) | Not permitted | No | No | The only one of the seven peptides the advisory panel voted against on July 24, 2026. | None scheduled |
| GHK-Cu | Partly permitted | No | Non-injectable forms only | Non-injectable forms have been in Category 1 since 2023. The injectable form came off Category 2 in April 2026. Also widely used as a cosmetic skincare ingredient. | Advisory panel review, February 2027 |
| Melanotan II | Under review | No | No | Taken off Category 2 in April 2026 after its nomination was withdrawn. | Advisory panel review, February 2027 |
| PEG-MGF | Under review | No | No | Taken off Category 2 in April 2026 after its nomination was withdrawn. | Advisory panel review, February 2027 |
| Dihexa | Under review | No | No | Not on the 503A bulks list. | Advisory panel review, February 2027 |
| Cathelicidin | Under review | No | No | Not on the 503A bulks list. | Advisory panel review, February 2027 |
| Retatrutide | Not permitted | No (in clinical trials) | No | An investigational weight-loss drug with four positive Phase 3 trials, not yet approved. The FDA has cited it in 20+ warning letters to online sellers. | Eli Lilly plans to apply for FDA approval in Q1 2027 |
| Semaglutide | FDA-approved | Yes (Ozempic, Wegovy) | Restricted | FDA-approved for type 2 diabetes and weight management, available by prescription. | — |
| Tirzepatide | FDA-approved | Yes (Mounjaro, Zepbound) | Restricted | FDA-approved for type 2 diabetes and weight management, available by prescription. | — |
| Bremelanotide (PT-141) | FDA-approved | Yes (Vyleesi) | Restricted | FDA-approved for low sexual desire in premenopausal women, by prescription. | — |
| Tesamorelin | FDA-approved | Yes (Egrifta) | Restricted | FDA-approved to reduce excess abdominal fat in people with HIV, by prescription. | — |
What this article is based on
Checked October 27, 2026. Primary FDA documents are listed first where available.
- FDA briefing document, Pharmacy Compounding Advisory Committee, July 2026
- GoodRx: Peptide Watch (reviewed October 16, 2026)
- Polsinelli: What FDA's latest actions mean for peptide compounding
- PharmExec: FDA panel votes to loosen restrictions for four peptides
- BSCG: What's changing with peptide regulation in 2026
About this content: The Peptide Verdict is an independent educational publication. Articles are researched and written with AI assistance, edited by our editorial team, and checked against the primary sources listed on each page. They are not reviewed by a medical professional and are not medical, legal, or pharmacy advice. Peptide regulations change quickly; always check the dates shown and confirm current rules. Talk to a licensed clinician before using any peptide or medication.